Presentation is loading. Please wait.

Presentation is loading. Please wait.

Elevated STAT3 phosphorylation and RANTES levels in tamoxifen-treated breast cancer cells. Elevated STAT3 phosphorylation and RANTES levels in tamoxifen-treated.

Published byMarjut Heikkinen Modified over 5 years ago

Similar presentations

Presentation on theme: "Elevated STAT3 phosphorylation and RANTES levels in tamoxifen-treated breast cancer cells. Elevated STAT3 phosphorylation and RANTES levels in tamoxifen-treated."— Presentation transcript:

1 Elevated STAT3 phosphorylation and RANTES levels in tamoxifen-treated breast cancer cells.
Elevated STAT3 phosphorylation and RANTES levels in tamoxifen-treated breast cancer cells. A, activated STAT3 status of tamoxifen-treated T47D cells was examined. After treatment with 1 μmol/L tamoxifen for 2 weeks, T47D- and tamoxifen-treated T47D cells were harvested and lysates were subjected to Western blotting. RANTES secretion levels were then determined by ELISA. Columns, means of triplicate samples; bars, SD. *, P < B, after RANTES treatment (50 ng/mL) for 2 weeks, cells were exposed to tamoxifen for 24 hours. Drug resistance levels were then determined by MTT assay. Columns, means of triplicate samples; bars, SD. *, P < 0.01, compared with control cells. C, ERα-positive primary breast cancer tissue slides were subjected to immunohistochemical staining for detection of pY-STAT3 and RANTES. D, the mechanism of maintenance of tamoxifen resistance is described. Eun Hee Yi et al. Mol Cancer Res 2013;11:31-42 ©2013 by American Association for Cancer Research

Download ppt "Elevated STAT3 phosphorylation and RANTES levels in tamoxifen-treated breast cancer cells. Elevated STAT3 phosphorylation and RANTES levels in tamoxifen-treated."

Similar presentations

Drug concentration (μM)

Drug concentration (μM)
IL-1β differentially regulates CXCL5 and CXCL8 protein secretion in NHTBE and NSCLC cells. IL-1β differentially regulates CXCL5 and CXCL8 protein secretion.

IL-1β differentially regulates CXCL5 and CXCL8 protein secretion in NHTBE and NSCLC cells. IL-1β differentially regulates CXCL5 and CXCL8 protein secretion.
Increase in beige/brown adipocyte characteristics in the xenografts from additional breast cancer cell lines. Increase in beige/brown adipocyte characteristics.

Increase in beige/brown adipocyte characteristics in the xenografts from additional breast cancer cell lines. Increase in beige/brown adipocyte characteristics.
Collagen-dependent phosphorylation of eIF4E in PDAC cells.

Collagen-dependent phosphorylation of eIF4E in PDAC cells.
TDP1 knockdown increases the sensitivity of rhabdomyosarcoma cell lines to CPT treatment. TDP1 knockdown increases the sensitivity of rhabdomyosarcoma.

TDP1 knockdown increases the sensitivity of rhabdomyosarcoma cell lines to CPT treatment. TDP1 knockdown increases the sensitivity of rhabdomyosarcoma.
Treatment with MI-773 causes changes in p53 status.

Treatment with MI-773 causes changes in p53 status.
Expression changes of specific epigenetic-controlled tumor-related genes by the prenatal/maternal BSp treatment. qRT-PCR and Western blot analysis were.

Expression changes of specific epigenetic-controlled tumor-related genes by the prenatal/maternal BSp treatment. qRT-PCR and Western blot analysis were.
Knocking down Wnt3 increases the cells' response to trastuzumab and reduces cells' invasiveness. Knocking down Wnt3 increases the cells' response to trastuzumab.

Knocking down Wnt3 increases the cells' response to trastuzumab and reduces cells' invasiveness. Knocking down Wnt3 increases the cells' response to trastuzumab.
JAK3A572V mutation causes constitutive JAK3 activity and IL-2–independent proliferation of NKTCL cells. JAK3A572V mutation causes constitutive JAK3 activity.

JAK3A572V mutation causes constitutive JAK3 activity and IL-2–independent proliferation of NKTCL cells. JAK3A572V mutation causes constitutive JAK3 activity.
Phosphorylation of AMPK-Thr172 before and after metformin treatment in muscle from subjects with type 2 diabetes. Phosphorylation of AMPK-Thr172 before.

Phosphorylation of AMPK-Thr172 before and after metformin treatment in muscle from subjects with type 2 diabetes. Phosphorylation of AMPK-Thr172 before.
Curcumin-generated ROS activates Chk1 and Chk2 kinases.

Curcumin-generated ROS activates Chk1 and Chk2 kinases.
TFAP2A interacts with HIF-1α and regulates VEGF expression and cell proliferation. TFAP2A interacts with HIF-1α and regulates VEGF expression and cell.

TFAP2A interacts with HIF-1α and regulates VEGF expression and cell proliferation. TFAP2A interacts with HIF-1α and regulates VEGF expression and cell.
Recognition of naturally processed HTLV-1 Tax protein derived from HAM patient's PBMC. A, HTLV-1 Tax protein content was evaluated by Western blot analysis.

Recognition of naturally processed HTLV-1 Tax protein derived from HAM patient's PBMC. A, HTLV-1 Tax protein content was evaluated by Western blot analysis.
Imatinib mesylate inhibits collagen synthesis in human breast stromal fibroblasts. Imatinib mesylate inhibits collagen synthesis in human breast stromal.

Imatinib mesylate inhibits collagen synthesis in human breast stromal fibroblasts. Imatinib mesylate inhibits collagen synthesis in human breast stromal.
Immunohistochemical detection of 8-OHdG by use of the 1F7 monoclonal antibody in oligomer-treated PC3 prostate cancer cells. a, control untreated peripheral.

Immunohistochemical detection of 8-OHdG by use of the 1F7 monoclonal antibody in oligomer-treated PC3 prostate cancer cells. a, control untreated peripheral.
CDCP1 is required for invadopodia formation and ECM degradation by human breast cancer cells. CDCP1 is required for invadopodia formation and ECM degradation.

CDCP1 is required for invadopodia formation and ECM degradation by human breast cancer cells. CDCP1 is required for invadopodia formation and ECM degradation.
Epigenetic regulation of p16INK4a in human gastric cancer.

Epigenetic regulation of p16INK4a in human gastric cancer.
Protracted temozolomide (TMZ) treatment leads to acquired TMZ resistance in glioblastoma (GBM) cells in vivo. Protracted temozolomide (TMZ) treatment leads.

Protracted temozolomide (TMZ) treatment leads to acquired TMZ resistance in glioblastoma (GBM) cells in vivo. Protracted temozolomide (TMZ) treatment leads.
A, ATP production by PC3 prostate cancer cells after treatment with oligonucleotide/Lipofectin complexes. a, ATP production by PC3 prostate cancer cells.

A, ATP production by PC3 prostate cancer cells after treatment with oligonucleotide/Lipofectin complexes. a, ATP production by PC3 prostate cancer cells.
Silencing hOGG1 triggers caspase-3 and caspase-7 activation in response to H2O2 in GM00637 cells. Silencing hOGG1 triggers caspase-3 and caspase-7 activation.

Silencing hOGG1 triggers caspase-3 and caspase-7 activation in response to H2O2 in GM00637 cells. Silencing hOGG1 triggers caspase-3 and caspase-7 activation.

Similar presentations

Ads by Google